{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Watanabe D"],"funding":["MEXT | Japan Society for the Promotion of Science","MEXT | Japan Society for the Promotion of Science (JSPS)","Japan Agency for Medical Research and Development","Ministry of Education, Culture, Sports, Science and Technology","MEXT | JST | Core Research for Evolutional Science and Technology","MEXT | JST | Core Research for Evolutional Science and Technology (CREST)","Ministry of Education, Culture, Sports, Science and Technology (MEXT)","Japan Agency for Medical Research and Development (AMED)"],"pagination":["8975"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11486946"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15(1)"],"pubmed_abstract":["The single-molecule tracking of transmembrane receptors in living cells has provided significant insights into signaling mechanisms, such as mobility and clustering upon their activation/inactivation, making it a potential screening method for drug discovery. Here we show that single-molecule tracking-based screening can be used to explore compounds both detectable and undetectable by conventional methods for disease-related receptors. Using an automated system for a fast large-scale single-molecule analysis, we screen for epidermal growth factor receptor (EGFR) from 1134 of FDA approved drugs. The 18 hit compounds include all EGFR-targeted tyrosine kinase inhibitors (TKIs) in the library that suppress any phosphorylation-dependent mobility shift of EGFR, proving the concept of this approa"],"journal":["Nature communications"],"pubmed_title":["Single molecule tracking based drug screening."],"pmcid":["PMC11486946"],"funding_grant_id":["18H05414","18H01839","JP23ym0126815","JPMJCR21E1","22H02593"],"pubmed_authors":["Ueda M","Watanabe D","Yasui M","Hiroshima M"],"additional_accession":[]},"is_claimable":false,"name":"Single molecule tracking based drug screening.","description":"The single-molecule tracking of transmembrane receptors in living cells has provided significant insights into signaling mechanisms, such as mobility and clustering upon their activation/inactivation, making it a potential screening method for drug discovery. Here we show that single-molecule tracking-based screening can be used to explore compounds both detectable and undetectable by conventional methods for disease-related receptors. Using an automated system for a fast large-scale single-molecule analysis, we screen for epidermal growth factor receptor (EGFR) from 1134 of FDA approved drugs. The 18 hit compounds include all EGFR-targeted tyrosine kinase inhibitors (TKIs) in the library that suppress any phosphorylation-dependent mobility shift of EGFR, proving the concept of this approa","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Oct","modification":"2025-04-04T20:55:24.622Z","creation":"2025-04-04T20:55:24.622Z"},"accession":"S-EPMC11486946","cross_references":{"pubmed":["39420015"],"doi":["10.1038/s41467-024-53432-w"]}}